LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for MEDNAX, Inc. (NYSE: MD), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MD. The Company announced on October 18, 2017, that it has acquired Houston-based private radiology physician group, Synergy Radiology Associates. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MD. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=MD

Acquisition Details

  • The acquisition was a cash and equity transaction and it is expected to be immediately accretive to earnings. The financial terms of the transaction remained undisclosed.
  • MEDNAX's affiliated radiologists will read more than 11 million studies annually after the transaction is completed.
  • As a result of the acquisition, 10 physician group practices have become part of MEDNAX in 2017.

Acquisition Enables MEDNAX to Expand its Radiology Physician Services

Roger J. Medel, M.D., Chief Executive Officer (CEO) of MEDNAX, stated that the Company further expands its radiology physician services and enhances its integrated physician services offering through the acquisition. MEDNAX is a valuable partner to radiology practices, offering world-class technological capabilities through vRad combined with MEDNAX's own practice-management expertise and physician-centric leadership. Medel added that the Company's partnership with Synergy Radiology Associates is very exciting, particularly given the group's prominent position in the field and its strategic partnerships with several key healthcare systems.

Partnership Allows Synergy Radiology Associates to Gain Support of the Most Technologically Advanced PACS and RIS System

Walid K. Adham, M.D., President and CEO of Synergy Radiology Associates, expressed that a partnership with MEDNAX is the natural next step as it will allow Synergy Radiology Associates to continue on a path of growth while gaining the support of the most technologically advanced PACS and RIS system in the industry, the vRad platform. Both the Companies also share a common vision of creating the most advanced radiology practice in the country. Adham added that Synergy Radiology Associates is looking forward to collaborating with its new partners across the country, which will facilitate large-scale data collection, clinical research, and quality initiatives that will impact the health of the population in a way that could never be achieved by any radiology practice individually.

Other Radiology Services Practice Acquisitions of MEDNAX in 2017

The Company acquired Jefferson Radiology, PC and Jefferson Imaging Associates, LLC based in Hartford, Connecticut, on September 28, 2017, to expand its radiology services.

MEDNAX completed the acquisition of Radiology Associates of South Florida (RASF), based in Miami, Florida, on August 23, 2017.

On January 30, 2017, the Company acquired Radiology Alliance, PC and Infinity Management, LLC based in Nashville, Tennessee.

About MEDNAX, Inc.

Founded in 1979, MEDNAX is a Health Solutions Partner that comprises the nation's leading providers of neonatal, anesthesia, maternal-fetal, and pediatric physician subspecialty services. The Company is headquartered in Florida, United States.

About Synergy Radiology Associates

Established in 2011 through the combination of three established radiology groups, Synergy Radiology Associates is Houston's premier radiology team comprised of more than 60 Board Certified Radiologists, a highly skilled clinical staff, and a vast group of support professionals.

Last Close Stock Review

On Thursday, October 19, 2017, the stock closed the trading session at $44.51, rising 5.67% from its previous closing price of $42.12. A total volume of 1.35 million shares have exchanged hands, which was higher than the 3-month average volume of 1.27 million shares. MEDNAX's stock price advanced 5.65% in the last one month. The stock is trading at a PE ratio of 14.15 and currently has a market cap of $4.22 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily